|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500096464 |
|
最近更新日期: Date of Last Refreshed on: |
2025-01-24 09:22:11 |
|
注册时间: Date of Registration: |
2025-01-24 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
99mTc-FAPI SPECT/CT诊断骨折相关感染准确性的单中心、非劣效、前瞻性临床研究 |
|
Public title: |
A single center, non inferiority, prospective clinical study on the accuracy of 99mTc FAPI SPECT/CT diagnosis of fracture related infections |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
99mTc-FAPI SPECT/CT诊断骨折相关感染准确性的单中心、非劣效、前瞻性临床研究 |
|
Scientific title: |
A single center, non inferiority, prospective clinical study on the accuracy of 99mTc FAPI SPECT/CT diagnosis of fracture related infections |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
黄定德 |
研究负责人: |
黄定德 |
|
Applicant: |
Huang Dingde |
Study leader: |
Huang Dingde |
|
申请注册联系人电话: Applicant telephone: |
+86 13110133297 |
研究负责人电话: Study leader's telephone: |
+86 23 68766578 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
huangdingde@126.com |
研究负责人电子邮件: Study leader's E-mail: |
huangdingde@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国人民解放军陆军军医大学第一附属医院核医学科 |
研究负责人通讯地址: |
重庆市沙坪坝区高滩岩正街29号 |
|
Applicant address: |
Nuclear Medicine Discipline of the First Affiliated Hospital of the PLA Army Medical University |
Study leader's address: |
No 29 Gaotanyan Main Street Shapingba District Chongqing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国人民解放军陆军军医大学第一附属医院核医学科 |
||
|
Applicant's institution: |
Nuclear Medicine Discipline of the First Affiliated Hospital of the PLA Army Medical University |
||
|
研究负责人所在单位: |
中国人民解放军陆军军医大学第一附属医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Army Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(A)KY2024204 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军陆军军医大学第一附属医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the First Affiliated Hospital of Army Medical University PLA |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-12-18 00:00:00 |
||
|
伦理委员会联系人: |
贺莉 |
||
|
Contact Name of the ethic committee: |
He Li |
||
|
伦理委员会联系地址: |
重庆市沙坪坝区高滩岩正街29号 |
||
|
Contact Address of the ethic committee: |
No 29 Gaotanyan Main Street Shapingba District Chongqing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 68754035 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
cqhl13@qq.com |
|
研究实施负责(组长)单位: |
中国人民解放军陆军军医大学第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Army Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市沙坪坝区高滩岩正街29号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No 29 Gaotanyan Main Street Shapingba District Chongqing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
99mTc-FAPI SPECT/CT诊断骨折相关感染准确性的单中心、非劣效、前瞻性临床研究 |
||||||||||||||||||||||
|
Source(s) of funding: |
A single center, non inferiority, prospective clinical study on the accuracy of 99mTc FAPI SPECT/CT |
||||||||||||||||||||||
|
Target disease: |
Infection related to sexual fractures |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
诊断试验 |
||||||||||||||||||||||
|
Study type: |
Diagnostic test |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
诊断试验诊断准确性 |
||||||||||||||||||||||
|
Study design: |
Diagnostic test for accuracy |
||||||||||||||||||||||
|
研究目的: |
以99mTc-FAPI为分子探针建立SPECT/CT显像技术,以手术组织标本的病理为“金标准”,与目前公认的诊断骨折相关感染的最佳影像学方法18F-FDG PET/CT进行对比研究,建立骨折相关感染的术前诊断的影像学新方法,为骨折相关感染的临床诊疗决策提供依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
Establishing SPECT/CT imaging technology using 99mTc FAPI as a molecular probe, with the pathology of surgical tissue specimens as the "gold standard", and comparing it with the currently recognized best imaging method for diagnosing fracture related infections, 18F-FDG PET/CT, to establish a new imaging method for preoperative diagnosis of fracture related infections and provide a basis for clinical diagnosis and treatment decisions of fracture related infections. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄>=18 岁。 2.四肢长骨有开放性骨折或开放性/闭合性骨折内固定手术史。 3. 临床怀疑为慢性骨折相关感染且在我院接受手术治疗。 依据国内外发表的专家共识,怀疑为骨折相关感染的标准包括 符合至少一项临床表现标准:局部新发非负重状态下的渐进性疼痛、伤口血肿、渗出等,或局部的窦道、流脓、伤口愈合欠佳等。 符合至少一项影像标准(CT 或 MRI):骨折端或植入物周围见骨溶解、内固定松动、死骨形成、骨不连、非骨折部位或已愈合的骨折部位 骨膜反应。 伴或不伴实验室检查异常:血清炎症标志物如红细胞沉降率、白细胞计数、C 反应蛋白出现二次上升或持续增高 4.每位患者至少存在一个符合上述标准的感染病灶(本研究以病灶为研 究对象,即样本量为病灶数量),若一名患者存在多个病灶,每个病灶均进行 影像学及病理学检查 5.拟行 Masquelet 重建术治疗 6. 同意进行 99mTc-FAPI SPECT/CT 显像和 18F-FDG PET/CT 显像。 7. 能够配合完成检查和随访。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age>=18 years. 2. History of open fracture or open/closed fracture internal fixation surgery on the long bones of the limbs. 3. Clinically suspected chronic fracture-related infection and undergoing surgery in our hospital. According to the expert consensus published at home and abroad, the criteria for suspicion of fracture-related infection include: Meet at least one clinical manifestation criterion: progressive pain, wound hematoma, exudation, etc. in a localized new-onset non-weight-bearing state, or local sinus tracts, pus, poor wound healing, etc. Meets at least one imaging criterion (CT or MRI): osteolysis, loosening of internal fixation, dead bone formation, nonunion, non-fracture site, or healed fracture site at the fracture end or around the implant Periosteal reaction. With or without laboratory abnormalities: serum inflammatory markers such as erythrocyte sedimentation rate, white blood cell count, and C-reactive protein are twice elevated or persistently elevated 4. Each patient has at least one infectious lesion that meets the above criteria (this study is based on lesions Subjects, i.e., the sample size is the number of lesions), if a patient has more than one lesion, each lesion is performed Imaging and pathological tests 5. Masquelet reconstruction treatment is proposed 6. Agree to perform 99mTc-FAPI SPECT/CT imaging and 18F-FDG PET/CT imaging. 7. Able to cooperate with the completion of examinations and follow-ups. |
||||||||||||||||||||||
|
排除标准: |
1.临床判断为急性骨折相关感染。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Clinically diagnosed as acute fracture related infection. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-02-01 00:00:00至 To 2027-10-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-02-01 00:00:00 至 To 2026-09-01 00:00:00 |
|
诊断试验: Diagnostic Tests: |
|
||||||||||||||||||||||||||||
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF;EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF;EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |